GigaGen
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
407 Cabot Rd, South San Francisco, Calif...Phone Number
(415) 978-2101Website
www.gigagen.comRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About GigaGen
GigaGen is a biopharmaceutical company based in San Carlos, California, specializing in antibody drug discovery using advanced single-cell technologies. The company focuses on developing novel recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, and cancers, with a commitment to revolutionizing treatment options. GigaGen's innovative platforms enable the recreation of complete immune repertoires, leading to the creation of highly potent antibody drugs, including its lead oncology asset, GIGA-564. The company aims to address life-threatening diseases by leveraging its proprietary technology to discover and develop transformative antibody therapies.Explore more
GigaGen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GigaGen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when GigaGen launches new products
Check out if GigaGen is spiking on competitors!
GigaGen, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once GigaGen has new funding data
Check if GigaGen has recently received funding, and reach out quickly before it becomes old news!
Click to see if GigaGen had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on GigaGen recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at GigaGen
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to GigaGen
Compare insights from companies similar to GigaGen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
GigaGen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GigaGen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GigaGen.
GigaGen financials insights
Gather financial insights about GigaGen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$36.1M
2020
Debt
$350K
GigaGen Tech Stack
A closer look at the technologies used by GigaGen
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Research & Development, Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations
Project
A mid-level source has indicated that the largest upcoming initiative is an IT overhaul and the organization will focus on an enterprise resource planning (ERP) integration to support these initiatives.
Integration, Enterprise Software
Project
Implementation, Contingent Workforce, Business Development, Enterprise Software, Operating Systems
GigaGen News & Media
GigaGen Secures $135M BARDA Contract For Biothreat Therapies
Will advance innovative therapies against naturally emerging and intentional biological threats.GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programsGigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GigaGen
Sign Up For FreeTo access detailed company insights
GigaGen is a biopharmaceutical company based in San Carlos, California, specializing in antibody drug discovery using advanced single-cell technologies. The company focuses on developing novel recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, and cancers, with a commitment to revolutionizing treat... Read More
